Aeglea's crossover

How Aeglea's B round could set the company up for a future IPO

The series B syndicate assembled by Aeglea Biotherapeutics Inc. has the hallmarks of a pre-IPO round. With a lead therapeutic enzyme on the brink of entering the clinic for Orphan diseases and cancer metabolism, the company has brought in

Read the full 391 word article

How to gain access

Continue reading with a
two-week free trial.